NASDAQ:AQST - Aquestive Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.67
  • Forecasted Upside: 240.29 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.13 (-2.93%)

This chart shows the closing price for AQST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aquestive Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AQST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AQST

Analyst Price Target is $14.67
▲ +240.29% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Aquestive Therapeutics in the last 3 months. The average price target is $14.67, with a high forecast of $30.00 and a low forecast of $7.00. The average price target represents a 240.29% upside from the last price of $4.31.

This chart shows the closing price for AQST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Aquestive Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/24/2021WedbushReiterated RatingBuy$30.00Medium
3/29/2021Lake Street CapitalReiterated RatingMarket Perform ➝ Buy$7.00High
3/15/2021HC WainwrightReiterated RatingBuy$14.00High
1/22/2021HC WainwrightReiterated RatingBuy$14.00Low
9/28/2020BMO Capital MarketsLower Price Target$18.00 ➝ $13.00High
9/28/2020Lake Street CapitalBoost Price TargetPositive ➝ Buy$7.00 ➝ $10.00High
9/28/2020HC WainwrightLower Price TargetBuy$15.00 ➝ $14.00High
9/28/2020Royal Bank of CanadaLower Price TargetOutperform$8.00 ➝ $7.00High
9/28/2020JMP SecuritiesLower Price TargetOutperform$23.00 ➝ $17.00High
9/2/2020WedbushReiterated RatingBuy$33.00Medium
8/13/2020WedbushReiterated RatingBuy$33.00Medium
8/6/2020Royal Bank of CanadaReiterated RatingBuy$8.00Low
7/6/2020WedbushReiterated RatingBuy$31.00Medium
6/30/2020HC WainwrightReiterated RatingBuy$15.00Medium
6/30/2020WedbushReiterated RatingBuy$31.00Medium
5/22/2020HC WainwrightReiterated RatingBuy$13.00 ➝ $15.00High
5/6/2020WedbushReiterated RatingBuy$31.00High
4/22/2020WedbushReiterated RatingBuy$31.00Medium
4/21/2020HC WainwrightReiterated RatingBuy$13.00Medium
4/5/2020WedbushReiterated RatingBuy$31.00High
3/25/2020Royal Bank of CanadaReiterated RatingBuy$8.00Low
3/22/2020WedbushReiterated RatingBuy$31.00Low
3/15/2020WedbushReiterated RatingBuy$36.00 ➝ $31.00High
2/10/2020WedbushBoost Price TargetOutperform$35.00 ➝ $36.00High
2/3/2020WedbushReiterated RatingBuy$35.00Medium
1/13/2020BMO Capital MarketsLower Price TargetOutperform$19.00 ➝ $18.00High
1/6/2020WedbushReiterated RatingBuy$35.00N/A
12/27/2019Lake Street CapitalReiterated RatingBuy$11.00 ➝ $10.00High
12/18/2019HC WainwrightReiterated RatingBuy$13.00Low
12/16/2019WedbushReiterated RatingBuy$37.00 ➝ $34.00Low
12/2/2019WedbushReiterated RatingBuy$37.00Low
12/2/2019HC WainwrightReiterated RatingBuy$12.00 ➝ $14.00High
11/25/2019WedbushReiterated RatingBuy$37.00High
10/16/2019WedbushReiterated RatingBuy$34.00High
9/30/2019WedbushReiterated RatingBuy$34.00Medium
7/5/2019WedbushSet Price TargetBuy$31.00Low
5/8/2019WedbushSet Price TargetBuy$31.00High
4/22/2019HC WainwrightInitiated CoverageBuy ➝ Buy$10.00Low
3/22/2019WedbushSet Price TargetBuy$30.00Low
3/15/2019BMO Capital MarketsLower Price TargetIn-Line ➝ Outperform$24.00 ➝ $21.00High
2/20/2019Lake Street CapitalReiterated RatingBuyHigh
1/3/2019Lake Street CapitalInitiated CoverageBuy ➝ Buy$14.00Low
12/20/2018WedbushSet Price TargetBuy AQST$30.00High
12/14/2018WedbushReiterated RatingBuy$30.00Medium
12/6/2018WedbushBoost Price TargetOutperform ➝ Outperform$29.00 ➝ $30.00High
11/7/2018Royal Bank of CanadaSet Price TargetBuy$24.00Low
10/25/2018WedbushSet Price TargetBuy$34.00Medium
10/10/2018WedbushSet Price TargetBuy$34.00Medium
9/12/2018WedbushInitiated CoverageOutperform$33.00Medium
8/20/2018Royal Bank of CanadaInitiated CoverageOutperform$23.00Low
8/20/2018JMP SecuritiesInitiated CoverageOutperform$29.00Low
8/20/2018BMO Capital MarketsInitiated CoverageOutperformLow
(Data available from 6/24/2016 forward)
Aquestive Therapeutics logo
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Read More

Today's Range

Now: $4.31
Low: $4.23
High: $4.50

50 Day Range

MA: $3.84
Low: $3.29
High: $4.44

52 Week Range

Now: $4.31
Low: $3.17
High: $9.47


55,069 shs

Average Volume

786,459 shs

Market Capitalization

$157.71 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Aquestive Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Aquestive Therapeutics in the last twelve months: BMO Capital Markets, HC Wainwright, JMP Securities, Lake Street Capital, Royal Bank of Canada, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for AQST.

What is the current price target for Aquestive Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Aquestive Therapeutics in the last year. Their average twelve-month price target is $15.17, suggesting a possible upside of 241.6%. Wedbush has the highest price target set, predicting AQST will reach $33.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $7.00 for Aquestive Therapeutics in the next year.
View the latest price targets for AQST.

What is the current consensus analyst rating for Aquestive Therapeutics?

Aquestive Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AQST will outperform the market and that investors should add to their positions of Aquestive Therapeutics.
View the latest ratings for AQST.

What other companies compete with Aquestive Therapeutics?

How do I contact Aquestive Therapeutics' investor relations team?

Aquestive Therapeutics' physical mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The company's listed phone number is 908-941-1900 and its investor relations email address is [email protected] The official website for Aquestive Therapeutics is